Nurix Therapeutics Extends Strategic Collaboration with Sanofi to Advance Oral STAT6 Degrader Program

Biotech company Nurix Therapeutics announced on April 9 the extension of its ongoing research program with Sanofi for oral small molecule drugs targeting STAT6 (Signal Transducer and Activator of Transcription 6) inhibitors. (Source: Interface)Original Link